Skip to main content
Insights

Investing in Sustainable Growth: Q2 2024

Innovation and the pace of technological change have been recurring themes in the Fundamental Growth and Core Equity team’s newsletters. Artificial Intelligence has consumed the market’s attention for some time now, but the theme of change and innovation has not been limited to the tech sector.

In healthcare, the introduction of GLP-1 drugs to treat obesity may have a significant impact on people’s health. This pharmaceutical innovation has parallels with Artificial Intelligence. Nvidia’s GPU chips were used for many years to power graphics for gaming but they have found new life in supporting large language models for generative AI. Similarly, GLP-1 drugs were used in the treatment of diabetes but were then found to be quite useful for weight loss giving them a much broader and more profound appeal.

A second parallel is that in AI, the release of ChatGPT has driven a frenzy of activity across industries as companies weigh how AI might help or hurt their businesses. Similarly with GLP-1s, the potential impact on health has set off activity well beyond pharmaceutical companies to include those in the consumer, medical equipment, and health insurance sectors. Another recurring theme in our newsletters is that we find some companies are better than others at reacting and adapting to change. This is something we call quality.

Fundamental Equity Analysis: Assessing the Investment Impact of Weight Loss Drugs Our first article in this newsletter explores many of the second-order effects of the release of GLP-1 weight loss drugs and looks at some of the companies that may benefit.

US Infrastructure and the Water Opportunity In our second article, we profile a less well-known company called Tetra Tech, an engineering and consulting firm that specializes in water and environmental related projects. The company is benefitting from secular themes such as infrastructure investment and adapting to climate change.

More on Equities